Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: A budget impact analysis

Journal of Medical Economics

Volumn 17, Issue 8, 2014, Pages 538-546

  Bajaj, Preeti S ^a   Veenstra, David L ^a   Goertz, Hans Peter ^b   Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GENENTECH INC   (United States)

Author keywords

Budget impact; Cost; Erlotinib; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; PACLITAXEL; PEMETREXED; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BUDGET; CANCER CHEMOTHERAPY; DRUG COST; DRUG TARGETING; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CANCER REGISTRY; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH INSURANCE; MIDDLE AGED; PATHOLOGY; UNITED STATES;

ADULT; AGED; BUDGETS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FOR-PROFIT INSURANCE PLANS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEER PROGRAM; UNITED STATES;

EID: 84904709109     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.912987     Document Type: Article

References (25)

1. What are the key statistics about lung cancer? American Cancer Society Web Site. http://www.cancer.org. Updated February 10, 2014. Accessed February 22, 2014.
2. National comprehensive cancer network. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 2013;11(6):645-53
3. National Comprehensive Cancer Network. NCCN Trends Results, July 2010: Non-Small Cell Lung Cancer and Mantle Cell Lymphoma. Fort Washington, PA. NCCN; 2010.
4. United States Census Bureau. Annual estimates of the resident population by sex and five-year age groups for the United States, April 1, 2000 to July 1, 2010. Washington, DC: U.S. Census Bureau; 2013.
5. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (2000-2010) 5Katrina/Rita Population Adjustment4. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2013. Accessed April 2013
6. Kaiser Family Foundation. Sources of supplemental coverage among Medicare Beneficiaries, 2009. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2009.
7. Sequist LV, Neal JW. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. UpToDate Website. http://www.uptodate.com/contents/ personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer. Updated June 12, 2013. Accessed June 21, 2013.
8. Hirsch FR, Bunn Jr PA. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-3
9. Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer 2012;78:245-52
10. Analysource. Analysource online: The online resource for drug pricing and deal information. 2013. www.analysource.com
11. Genentech, Inc. Clinical Study Report E4599. A randomized phase II/III trial of paclitaxel plus carbolplatin with or without bevacizumab in patients with advanced nonsquamous NSCLC. South San Francisco, CA: Genentech, Inc.; 2006.
12. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
13. F. Hoffman-La Roche Ltd. Clinical Study Report-Research Report 1050832. Basel, Switzerland: F. Hoffman-La Roche Ltd.; 2012
14. Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1963-9
15. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-9
16. Astellas Pharma US, Inc., and Genentech, Inc. Tarceva® Highlights of Prescribing Information. 2013.
17. Genentech, Inc. Avastin® Highlights of Prescribing Information. 2013.
18. Centers for Medicare and Medicaid Services. Diagnosis related group codes.
19. MoPath Fee Schedule.Palmetto GBA Web Site.http://palmettogba.com/med- icare. Updated April 1, 2013. Accessed April 6, 2013
20. Pfizer Labs. Xalkori® Highlights of Prescribing Information. 2013.
21. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
22. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1416-23
23. Centers for Medicare and Medicaid Services. Physician fee schedule (CY 2013). Baltimore, MD: CMS; 2013
24. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health: J Int Soc Pharmacoecon Outcomes Res 2014;17:5-14
25. International Agency for Research on Cancer. Cancer Incidence in Five Continents, Vol. IX. Lyon, France: World Health Organization; 2007.